Catalyst Event

Pfizer Inc (PFE) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

6/8/2026, 12:00:00 AM

OtherSentiment: Positive

The U.S. FDA approved an expanded indication for Hympavzi on June 8, 2026, for treating hemophilia A or B in patients aged 12+ and 6-11; given the expanded market reach, a 5% price impact is expected.

Korean Translation

2026년 6월 8일, 미국 FDA의 혈우병 치료제 힘파브지 적응증 확대 승인에 따른 시장 확대 기대로 약 5%의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline